Literature DB >> 15910598

Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas.

A Couvelard1, D O'Toole, R Leek, H Turley, A Sauvanet, C Degott, P Ruszniewski, J Belghiti, A L Harris, K Gatter, F Pezzella.   

Abstract

AIMS: To study the expression of hypoxia-regulated markers in pancreatic ductal adenocarcinomas (PA) in relationship to the presence of a fibrotic focus, angiogenesis quantification and clinical outcome. METHODS AND
RESULTS: The expression of hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, carbonic anhydrase 9 (CA9) and vascular endothelial growth factor (VEGF) was immunohistochemically detected in 50 PA and correlated with tumour characteristics, microvascular density (MVD) and survival. HIF-1alpha was expressed within tumour cells in 68%, HIF-2alpha in 46%, CA9 in 78% and VEGF in 52% of the cases. Stromal expression was also noted for HIF-2alpha and CA9 in, respectively, 42% and 48% of the cases. Tumour CA9 expression was associated with that of VEGF (P=0.004) and that of stromal HIF-2alpha (P=0.013), with the presence of a fibrotic focus (P=0.046) and with an increased MVD (P=0.034). Tumour VEGF expression correlated with the presence of a fibrotic focus (P=0.039) and a greater MVD (P=0.047). Both the presence of a fibrotic focus (P=0.0002) and high tumour CA9 expression (P=0.029) were associated with reduced overall survival.
CONCLUSION: The strong association of the presence of a fibrotic focus with CA9 expression and lower survival demonstrates that hypoxia-driven angiogenesis plays an important role in the progression of PA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15910598     DOI: 10.1111/j.1365-2559.2005.02160.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  39 in total

Review 1.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

Review 2.  Antiangiogenic therapy in human gastrointestinal malignancies.

Authors:  J Heidemann; D G Binion; W Domschke; T Kucharzik
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

Review 3.  HIF-1α -1790G>A polymorphism significantly increases the risk of digestive tract cancer: a meta-analysis.

Authors:  Xiao Sun; Ying-Di Liu; Wei Gao; Shao-Hua Shen; Meng Li
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

Review 4.  Role of pancreatic stellate cells and periostin in pancreatic cancer progression.

Authors:  Yang Liu; Lianfang Du
Journal:  Tumour Biol       Date:  2015-04-04

5.  Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis.

Authors:  Yong Gao; Zhiliang Jia; Xiangyu Kong; Qiang Li; David Z Chang; Daoyan Wei; Xiangdong Le; Huang Suyun; Shengdong Huang; Liwei Wang; Keping Xie
Journal:  Cancer Res       Date:  2011-06-14       Impact factor: 12.701

6.  Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis.

Authors:  Zipeng Lu; Maximilian Weniger; Kuirong Jiang; Stefan Boeck; Kai Zhang; Alexander Bazhin; Yi Miao; Jens Werner; Jan G D'Haese
Journal:  Target Oncol       Date:  2018-08       Impact factor: 4.493

7.  Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity.

Authors:  Zhiliang Jia; Yong Gao; Liwei Wang; Qiang Li; Jun Zhang; Xiangdong Le; Daoyan Wei; James C Yao; David Z Chang; Suyun Huang; Keping Xie
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

8.  Generation of an in vitro 3D PDAC stroma rich spheroid model.

Authors:  Matthew J Ware; Vazrik Keshishian; Justin J Law; Jason C Ho; Carlos A Favela; Paul Rees; Billie Smith; Sayeeduddin Mohammad; Rosa F Hwang; Kimal Rajapakshe; Cristian Coarfa; Shixia Huang; Dean P Edwards; Stuart J Corr; Biana Godin; Steven A Curley
Journal:  Biomaterials       Date:  2016-09-02       Impact factor: 12.479

9.  Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation.

Authors:  N Hiraoka; Y Ino; S Sekine; H Tsuda; K Shimada; T Kosuge; J Zavada; M Yoshida; K Yamada; T Koyama; Y Kanai
Journal:  Br J Cancer       Date:  2010-08-24       Impact factor: 7.640

Review 10.  Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells.

Authors:  Michael Friberg Bruun Nielsen; Michael Bau Mortensen; Sönke Detlefsen
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.